These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2854601)
1. Vaccine potential of a live avirulent herpes simplex virus. Thompson RL; Nakashizuka M; Stevens JG Microb Pathog; 1986 Aug; 1(4):409-16. PubMed ID: 2854601 [TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome. Thompson RL; Rogers SK; Zerhusen MA Virology; 1989 Oct; 172(2):435-50. PubMed ID: 2552657 [TBL] [Abstract][Full Text] [Related]
3. Biological characterization of a herpes simplex virus intertypic recombinant which is completely and specifically non-neurovirulent. Thompson RL; Stevens JG Virology; 1983 Nov; 131(1):171-9. PubMed ID: 6316649 [TBL] [Abstract][Full Text] [Related]
4. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain. Klein RJ; Kaley LA; Friedman-Kien AE Vaccine; 1984 Sep; 2(3):219-23. PubMed ID: 6099650 [TBL] [Abstract][Full Text] [Related]
5. DNA sequence and RNA transcription through a site of recombination in a non-neurovirulent herpes simplex virus intertypic recombinant. Thompson RL; Devi-Rao GV; Wagner EK Virus Genes; 1988 Jun; 1(3):275-86. PubMed ID: 2854325 [TBL] [Abstract][Full Text] [Related]
6. Partial rescue of herpes simplex virus neurovirulence with a 3.2 kb cloned DNA fragment. Thompson RL; Wagner EK Virus Genes; 1988 Jun; 1(3):261-73. PubMed ID: 2854324 [TBL] [Abstract][Full Text] [Related]
7. Virulence is not conserved in recombinants between herpes simplex virus types 1 and 2. Halliburton IW; Honess RW; Killington RA J Gen Virol; 1987 May; 68 ( Pt 5)():1435-40. PubMed ID: 3033143 [TBL] [Abstract][Full Text] [Related]
8. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the virulence genes of herpes simplex virus 2 by experimental infection in vivo with defined intertypic recombinants of a virulent HSV-2 X an avirulent HSV-1. Rösen A; Darai G Med Microbiol Immunol; 1985; 174(5):237-48. PubMed ID: 3003551 [TBL] [Abstract][Full Text] [Related]
12. Rescue of a herpes simplex virus type 1 neurovirulence function with a cloned DNA fragment. Thompson RL; Devi-Rao GV; Stevens JG; Wagner EK J Virol; 1985 Aug; 55(2):504-8. PubMed ID: 2991575 [TBL] [Abstract][Full Text] [Related]
13. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288 [TBL] [Abstract][Full Text] [Related]
14. A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice. Taha MY; Clements GB; Brown SM J Gen Virol; 1989 Mar; 70 ( Pt 3)():705-16. PubMed ID: 2543755 [TBL] [Abstract][Full Text] [Related]
15. Genetic and biological analyses of a herpes simplex virus intertypic recombinant reduced specifically for neurovirulence. Javier RT; Thompson RL; Stevens JG J Virol; 1987 Jun; 61(6):1978-84. PubMed ID: 3033324 [TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus type 2 establishes latency in the mouse footpad and in the sensory ganglia. Subak-Sharpe JH; Al-Saadi SA; Clements GB J Invest Dermatol; 1984 Jul; 83(1 Suppl):67s-71s. PubMed ID: 6330225 [TBL] [Abstract][Full Text] [Related]
17. Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Chrisp CE; Sunstrum JC; Averill DR; Levine M; Glorioso JC Lab Invest; 1989 Jun; 60(6):822-30. PubMed ID: 2543866 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice. McKendall RR Infect Immun; 1977 May; 16(2):717-9. PubMed ID: 193798 [TBL] [Abstract][Full Text] [Related]
19. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395 [TBL] [Abstract][Full Text] [Related]